A brief history of treatments for chilhood acute lymphoblastic leukaemia

被引:1
|
作者
Leverger, Guy
Baruchel, Andre [1 ,2 ]
Schaison, Gerard
机构
[1] Hop Armand Trousseau, F-75012 Paris, France
[2] Univ Paris 06, UMR 5938, F-75252 Paris 05, France
来源
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2009年 / 193卷 / 07期
关键词
PRECURSOR CELL; LYMPHOBLASTIC; LEUKEMIA-LYMPHOMA; CHILD; LEUKEMIA/THERAPEUTICS; MINIMAL RESIDUAL DISEASE; CHILDREN; CLASSIFICATION; THERAPY; PROGNOSIS; FRANCE;
D O I
10.1016/S0001-4079(19)32439-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute lymphoblastic leukaemia is the most frquent childhood malignancy The first effective drugs, which provided only short-lived complete remission, started to be used in the 1950s All the effective drugs currently in use were discovered in the 1960s, when the first multidrug chemotherapy regumens were shown to confer prolonged complete remission, raising the possibility of a cure Simultaneously, progress in our knowledge of leukaemic cells, and the identification of prognostic factors such as leukocytosis, age, cytogenetic and molecular abnormalities, and the early therapeutic response of leukaemic cells, led to randomized multicenter national and international trials As a result, the chance of cure increased gradually over the last three decades In rich countries, the overall survival rate among children with acute lymphoblastic leukaemia now reaches 85 to 90%
引用
收藏
页码:1495 / 1499
页数:5
相关论文
共 50 条
  • [41] Meningeosis leukaemica in adult acute lymphoblastic leukaemia
    Gökbuget, N
    Hoelzer, D
    JOURNAL OF NEURO-ONCOLOGY, 1998, 38 (2-3) : 167 - 180
  • [42] Meningeosis leukaemica in adult acute lymphoblastic leukaemia
    Nicola Gökbuget
    Dieter Hoelzer
    Journal of Neuro-Oncology, 1998, 38 : 167 - 180
  • [43] Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia
    Morley, N. J.
    Marks, D. I.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 159 - 164
  • [44] Risk Factors for Treatment Related Mortality in Childhood Acute Lymphoblastic Leukaemia
    Lund, Bendik
    Asberg, Ann
    Heyman, Mats
    Kanerva, Jukka
    Harila-Saari, Arja
    Hasle, Henrik
    Soderhall, Stefan
    Jonsson, Olafur Gisli
    Lydersen, Stian
    Schmiegelow, Kjeld
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 551 - 559
  • [45] Readiness for hospital discharge in primary caregivers for children with acute lymphoblastic leukaemia
    Lu, Feng
    Zhang, Ge
    Zhao, Xiufang
    Luo, Biru
    JOURNAL OF CLINICAL NURSING, 2022, 31 (21-22) : 3213 - 3221
  • [46] Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia
    Lehrnbecher, Thomas
    Schubert, Ralf
    Behl, Michael
    Koenig, Melanie
    Rose, Markus A.
    Koehl, Ulrike
    Meisel, Roland
    Laws, Hans-Jurgen
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (05) : 700 - 705
  • [47] Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy
    Ganzel, Chezi
    Devlin, Sean
    Douer, Dan
    Rowe, Jacob M.
    Stein, Eytan M.
    Tallman, Martin S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) : 50 - 55
  • [48] Updated AWMF Guideline on the Diagnosis and Treatment of Acute Lymphoblastic Leukaemia in Children
    Escherich, Gabriele
    Schrappe, Martin
    KLINISCHE PADIATRIE, 2022, 234 (06): : 363 - 367
  • [49] Pattern of relapse in paediatric acute lymphoblastic leukaemia in a tertiary care unit
    Siddiqui, Emad Uddin
    Kazi, Sayyeda Ghazala
    Habib, Muhammad Irfan
    Khan, Khalid Mehmood Ahmed
    Zia, Nukhba
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2016, 66 (08) : 961 - 967
  • [50] Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?
    Kodidela, Sunitha
    Chandra, Pradhan Suresh
    Dubashi, Biswajit
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (03) : 253 - 260